Designing phase II B trials in sarcopenia: The best target population
- First Online:
- 110 Downloads
Despite the existing limitations and controversies regarding the definition of sarcopenia and its clinical consequences, the current scientific evidence strongly suggests that muscle decline is a primary determinant of the disabling process (and likely of other major health-related events). In fact, the muscle loss (in terms of mass as well as strength) occurring with aging has been growingly associated with mobility impairment and disability in older persons. Unfortunately, current evidence is mainly from observational studies. Times are mature to begin testing interventions aimed at modifying the sarcopenia process through the design and development of specific clinical trials. Considering the emergence of many promising interventions towards this age-related condition (e.g., physical exercise [in particular, resistance training], testosterone, antioxidant supplementations), the need for Phase II trial designs is high. In the present report, we discuss which are the major issues related to the design of Phase II clinical trials on sarcopenia with particular focus on the participant’s characteristics to be considered as possible inclusion and exclusion criteria.
Key wordsSarcopenia clinical trials study design skeletal muscle aging muscle strength older persons
Unable to display preview. Download preview PDF.
- 1.Rosenberg IH. Sarcopenia origins and clinical relevance. JNutr. 1997;127(5 Suppl):990S.Google Scholar
- 7.Cesari M, Pahor M, Lauretani F, Zamboni V, Bandinelli S, Bernabei R et al. Skeletal Muscle and Mortality Results From the InCHLANTi Study. J Gerontol A Biol Sci Med Sci. 2009Google Scholar
- 27.Beenakker KG, Ling CH, Meskers CG, de Craen AJ, Stijnen T, Westendorp RG et al. Patterns of muscle strength loss with age in the general population and patients with a chronic inflammatory state. Ageing Res Rev. 2010Google Scholar
- 33.Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Ostir GV et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol ABiol SciMed Sci. 2000;55(4):M221.CrossRefGoogle Scholar
- 42.Goodpaster BH, Carlson CL, Visser M, Kelley DE, Scherzinger A, Harris TB et al. Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study. J AppI Physiol 2001;90(6):2157.Google Scholar